193 related articles for article (PubMed ID: 8099571)
1. Amplification of fgfr4 gene in human breast and gynecological cancers.
Jaakkola S; Salmikangas P; Nylund S; Partanen J; Armstrong E; Pyrhönen S; Lehtovirta P; Nevanlinna H
Int J Cancer; 1993 May; 54(3):378-82. PubMed ID: 8099571
[TBL] [Abstract][Full Text] [Related]
2. GST pi gene is frequently coamplified with INT2 and HSTF1 proto-oncogenes in human breast cancers.
Saint-Ruf C; Malfoy B; Scholl S; Zafrani B; Dutrillaux B
Oncogene; 1991 Mar; 6(3):403-6. PubMed ID: 1826346
[TBL] [Abstract][Full Text] [Related]
3. Visualization of INT2 and HST1 amplification in oral squamous cell carcinomas.
Lese CM; Rossie KM; Appel BN; Reddy JK; Johnson JT; Myers EN; Gollin SM
Genes Chromosomes Cancer; 1995 Apr; 12(4):288-95. PubMed ID: 7539284
[TBL] [Abstract][Full Text] [Related]
4. INT2 and ERBB2 amplification and ERBB2 expression in breast tumors from patients with different outcomes.
Pauley RJ; Gimotty PA; Paine TJ; Dawson PJ; Wolman SR
Breast Cancer Res Treat; 1996; 37(1):65-76. PubMed ID: 8750529
[TBL] [Abstract][Full Text] [Related]
5. Chromosome 11q13, c-erbB-2, and c-myc amplification in invasive breast carcinoma: clinicopathologic correlations.
Gaffey MJ; Frierson HF; Williams ME
Mod Pathol; 1993 Nov; 6(6):654-9. PubMed ID: 7905628
[TBL] [Abstract][Full Text] [Related]
6. Association of INT2/HST1 coamplification in primary breast cancer with hormone-dependent phenotype and poor prognosis.
Borg A; Sigurdsson H; Clark GM; Fernö M; Fuqua SA; Olsson H; Killander D; McGurie WL
Br J Cancer; 1991 Jan; 63(1):136-42. PubMed ID: 1989653
[TBL] [Abstract][Full Text] [Related]
7. Cyclin DI amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis.
Seshadri R; Lee CS; Hui R; McCaul K; Horsfall DJ; Sutherland RL
Clin Cancer Res; 1996 Jul; 2(7):1177-84. PubMed ID: 9816285
[TBL] [Abstract][Full Text] [Related]
8. High-throughput tissue microarray analysis of 11q13 gene amplification (CCND1, FGF3, FGF4, EMS1) in urinary bladder cancer.
Zaharieva BM; Simon R; Diener PA; Ackermann D; Maurer R; Alund G; Knönagel H; Rist M; Wilber K; Hering F; Schönenberger A; Flury R; Jäger P; Fehr JL; Mihatsch MJ; Gasser T; Sauter G; Toncheva DI
J Pathol; 2003 Dec; 201(4):603-8. PubMed ID: 14648664
[TBL] [Abstract][Full Text] [Related]
9. FGF4 and INT2 oncogenes are amplified and expressed in Kaposi's sarcoma.
Kiuru-Kuhlefelt S; Sarlomo-Rikala M; Larramendy ML; Söderlund M; Hedman K; Miettinen M; Knuutila S
Mod Pathol; 2000 Apr; 13(4):433-7. PubMed ID: 10786811
[TBL] [Abstract][Full Text] [Related]
10. Genetic markers as prognostic indicators in breast cancer.
Wolman SR; Pauley RJ; Mohamed AN; Dawson PJ; Visscher DW; Sarkar FH
Cancer; 1992 Sep; 70(6 Suppl):1765-74. PubMed ID: 1355402
[TBL] [Abstract][Full Text] [Related]
11. Classical gene amplifications in human breast cancer are not associated with distant solid metastases.
Driouch K; Champème MH; Beuzelin M; Bièche I; Lidereau R
Br J Cancer; 1997; 76(6):784-7. PubMed ID: 9310246
[TBL] [Abstract][Full Text] [Related]
12. Int-2/FGF3 amplification is a better independent predictor of relapse than c-myc and c-erbB-2/neu amplifications in primary human breast cancer.
Champème MH; Bièche I; Hacène K; Lidereau R
Mod Pathol; 1994 Dec; 7(9):900-5. PubMed ID: 7892157
[TBL] [Abstract][Full Text] [Related]
13. CCND1 and FGFR1 coamplification results in the colocalization of 11q13 and 8p12 sequences in breast tumor nuclei.
Bautista S; Theillet C
Genes Chromosomes Cancer; 1998 Aug; 22(4):268-77. PubMed ID: 9669664
[TBL] [Abstract][Full Text] [Related]
14. Amplified genes in cancer in upper digestive tract.
Yoshida T; Sakamoto H; Terada M
Semin Cancer Biol; 1993 Feb; 4(1):33-40. PubMed ID: 8095412
[TBL] [Abstract][Full Text] [Related]
15. Cyclin gene amplification and overexpression in breast and ovarian cancers: evidence for the selection of cyclin D1 in breast and cyclin E in ovarian tumors.
Courjal F; Louason G; Speiser P; Katsaros D; Zeillinger R; Theillet C
Int J Cancer; 1996 Aug; 69(4):247-53. PubMed ID: 8797862
[TBL] [Abstract][Full Text] [Related]
16. The 11q13 amplicon of a mammary carcinoma cell line.
Lafage M; Nguyen C; Szepetowski P; Pébusque MJ; Simonetti J; Courtois G; Gaudray P; deLapeyriere O; Jordan B; Birnbaum D
Genes Chromosomes Cancer; 1990 Sep; 2(3):171-81. PubMed ID: 2078507
[TBL] [Abstract][Full Text] [Related]
17. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer.
Paterson MC; Dietrich KD; Danyluk J; Paterson AH; Lees AW; Jamil N; Hanson J; Jenkins H; Krause BE; McBlain WA
Cancer Res; 1991 Jan; 51(2):556-67. PubMed ID: 1670762
[TBL] [Abstract][Full Text] [Related]
18. Proto-oncogene amplification and human breast tumor phenotype.
Adnane J; Gaudray P; Simon MP; Simony-Lafontaine J; Jeanteur P; Theillet C
Oncogene; 1989 Nov; 4(11):1389-95. PubMed ID: 2554239
[TBL] [Abstract][Full Text] [Related]
19. BCL-1 participates in the 11q13 amplification found in breast cancer.
Theillet C; Adnane J; Szepetowski P; Simon MP; Jeanteur P; Birnbaum D; Gaudray P
Oncogene; 1990 Jan; 5(1):147-9. PubMed ID: 2181375
[TBL] [Abstract][Full Text] [Related]
20. ERBB2 amplification in breast cancer with a high rate of proliferation.
Borg A; Baldetorp B; Fernö M; Killander D; Olsson H; Sigurdsson H
Oncogene; 1991 Jan; 6(1):137-43. PubMed ID: 1671531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
